Clinical trials: Metastatic Cancers
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety…
- Trial name
- REZILIENT1 (NCT04036682)
- Testing
- CLN-081
- Where
- 64 sites in United States, Hong Kong and 7 more
- Volunteers
- 284 people
- Sponsor
- Cullinan Therapeutics Inc.
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Recurrent or Metastatic Solid Tumors
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
- Trial name
- A-337 (NCT06093698)
- Testing
- Recombinant Anti-EpCAM-CD3 Antibody Injection
- Volunteers
- 94 people
- Sponsor
- ITabMed Co., Ltd.
Non Small Cell Lung Cancer
A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
The primary objective of the study is to collect epidemiological data on EGFR mutation status [M+(mutation positive), M-(mutation negative)] in a population of predominantly Caucasian ethnicity, and to correlate EGFR mutation…
- Trial name
- REASON (NCT01153399)
- Where
- 9 sites in Greece
- Volunteers
- 589 people
- Sponsor
- AstraZeneca
Neoplasms
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.
- Trial name
- NCT04397276
- Testing
- JNJ-70218902
- Where
- 7 sites in Canada, Israel and 1 more
- Volunteers
- 82 people
- Sponsor
- Janssen Research & Development, LLC
Cholangiocarcinoma
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable…
- Trial name
- NCT04238715
- Testing
- E7090
- Where
- 56 sites in China, Japan
- Volunteers
- 63 people
- Sponsor
- Eisai Co., Ltd.
Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma
- Trial name
- CD205SHUTTLE (NCT03403725)
- Testing
- MEN1309
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Menarini Group
Non-Small Cell Lung Cancer
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with…
- Trial name
- NCT00257608
- Testing
- bevacizumab, erlotinib HCl
- Where
- 247 sites in United States, Argentina and 15 more
- Volunteers
- 1,145 people
- Sponsor
- Genentech, Inc.
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Biliary Tract Cancer
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 compared with the investigator's choice of protocol in patients with locally advanced or…
- Trial name
- NCT07582315
- Testing
- BL-B01D1, Oxaliplatin, Calcium levofolinate
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
- Trial name
- NCT00380835
- Testing
- Amrubicin
- Where
- 28 sites in United States
- Volunteers
- 66 people
- Sponsor
- Celgene Corporation
Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of…
- Trial name
- NCT05636215
- Testing
- IBI354
- Where
- 6 sites in Australia, China
- Volunteers
- 368 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Melanoma Metastatic, Melanoma, Skin
Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
The goal of this observational study is to assess whether the IOpener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma).
- Conditions
- Melanoma Metastatic, Melanoma, Skin, Melanoma Stage III or IV, Melanoma Advanced
- Trial name
- COMO (NCT06784778)
- Testing
- PBMC Kinase Activity Profile
- Where
- 3 sites in Germany
- Volunteers
- 196 people
- Sponsor
- Pamgene International B.V.
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Phase II, non-randomized, multicenter, prospective study designed to test the efficacy and safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma.
- Trial name
- NCT01253096
- Testing
- Intratumoral injections of L19IL2
- Where
- 3 sites in Austria, Germany
- Volunteers
- 25 people
- Sponsor
- Philogen S.p.A.
Bone-Metastatic, Castration-Resistant Prostate Cancer
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 months.
- Trial name
- NCT01074138
- Testing
- KX2-391
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Athenex, Inc.
Solid Tumors With FGFR2 Alterations, Adult
A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic…
- Trial name
- NCT06800196
- Testing
- KNT-0916
- Where
- China
- Volunteers
- 151 people
- Sponsor
- KinoTeck Therapeutics Co., Ltd
Metastatic Prostate Cancer
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
- Trial name
- SEACLIFF (NCT07181161)
- Testing
- AZD0516, AZD9574
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Tumor, Solid, Tumor
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
- Conditions
- Tumor, Solid, Tumor, Advanced Solid Tumor
- Trial name
- NCT05661461
- Testing
- nab-sirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.